Welcome to our dedicated page for Monogram Orthopaedics news (Ticker: MGRM), a resource for investors and traders seeking the latest updates and insights on Monogram Orthopaedics stock.
Monogram Technologies Inc (NASDAQ: MGRM) pioneers AI-driven orthopedic solutions combining surgical robotics, 3D printing, and machine vision. This dedicated news hub provides investors and healthcare professionals with essential updates on the company's innovative approaches to joint replacement technology.
Access timely announcements including regulatory submissions, clinical trial progress, and strategic partnerships. Our curated collection features earnings reports, product development milestones, and analyses of the company's unique robotic surgical ecosystem designed for precision implant placement.
Key updates cover advancements in autonomous surgical systems, FDA clearance processes, and collaborations with medical institutions. Bookmark this page for verified information about Monogram's integration of digital imaging analytics, and bone-sparing surgical techniques that aim to redefine orthopedic care standards.
Monogram Technologies (NASDAQ:MGRM), an AI-driven robotics company focused on orthopedic surgery, has reported its financial results for Q4 and full-year 2024. Key highlights include:
The company completed supplemental testing and submitted its response to the FDA's Additional Information Request (AIR) for their mBȏs™ Total Knee Arthroplasty System. They are awaiting FDA clearance for commercialization in the US.
Financial highlights for 2024:
- R&D expenses decreased 17% to $8.8 million
- Marketing expenses reduced 30% to $2.1 million
- G&A expenses increased 9% to $4.4 million
- Net loss of $16.3 million
- Cash position of $15.7 million as of December 31, 2024
Notable achievements include:
- Closed an oversubscribed $13 million public offering
- Advanced partnership with Shalby for clinical trials in India
- Named Orthopedic Joint Replacement Company of the Year 2024
- Management completed $1 million in open market stock purchases
Monogram Technologies (NASDAQ:MGRM) has reported its financial results for Q4 and full year 2024. The company completed supplemental testing and submitted its response to the FDA's Additional Information Request (AIR) for its mBȏs™ TKA System. Key highlights include:
- Closed an oversubscribed $13M public offering
- Management purchased $1M of common stock in open market
- Named Orthopedic Joint Replacement Company of the Year 2024
Financial results for FY2024:
- R&D expenses: $8.8M (down 17% YoY)
- Marketing expenses: $2.1M (down 30% YoY)
- G&A expenses: $4.4M (up 9% YoY)
- Net loss: $16.3M (vs $13.7M in 2023)
- Cash position: $15.7M as of December 31, 2024
The company is advancing its collaboration with Shalby for clinical trials in India and awaiting FDA clearance decision for U.S. commercialization.
Monogram Technologies (NASDAQ: MGRM), an AI-driven robotics company specializing in orthopedic surgery solutions, has announced its participation in the upcoming 37th Annual ROTH Conference. The event will take place from March 16-18, 2025, at the Laguna Cliffs Marriott Resort & Spa in Dana Point, California.
The company will be represented by CEO Ben Sexson and CFO Noel Knape, who will conduct one-on-one meetings with institutional investors during this invitation-only event. Interested investors can schedule meetings through their conference representatives or by contacting MGRM@mzgroup.us or Chris Tyson at (949) 491-8235.
Monogram Technologies (NASDAQ:MGRM), an AI-driven robotics company specializing in orthopedic surgery, has scheduled its Q4 and Full Year 2024 financial results conference call for March 12, 2025, at 4:30 p.m. Eastern Time. The event will feature CEO Ben Sexson and CFO Noel Knape, who will present the company's financial performance for the period ending December 31, 2024, along with regulatory updates and key milestones.
A detailed press release will be issued before the call, and the presentation will be accessible through the company's investor relations website. Participants can join the webcast through the provided StreamYard link, with a Q&A session following the main presentation.
Monogram Technologies (NASDAQ:MGRM) has provided key updates on its mBôs TKA System. The company has completed supplemental testing and submitted its formal response to the FDA's Additional Information Request (AIR) from September 30, 2024, awaiting clearance decision for U.S. commercialization.
In partnership with Shalby , Monogram conducted an Investigator Meeting in Ahmedabad, India (January 31-February 1, 2025) to prepare for a multicenter clinical trial. The trial, managed by Reliance Life Sciences, aims to evaluate the system's safety and effectiveness.
Notable technological improvements include a 300% increase in feed rate for the cutting system. The company's autonomous robotic platform is being developed to be time-competitive with manual surgery while maintaining accuracy and safety, positioning itself as a potential market disruptor in orthopedic robotics.
Monogram Technologies (NASDAQ:MGRM) provided an update following its Submission Issue Request (SIR) meeting with the FDA regarding its 510(k) premarket filing for the mBôs TKA System. The company's July 2024 application received an Additional Information Request (AIR) on September 30, putting the application on hold. Following the December 17 SIR meeting, management believes its comprehensive plans will satisfy the FDA without requiring clinical data.
The company anticipates providing a complete AIR response in Q1 2025. Key upcoming milestones include seeking regulatory clearance for clinical trials in India with Shalby Hospitals, shipping a robot to India for trial training by January 2025, and pursuing FDA clearance for the mBôs TKA System while expanding domestic and international relationships.
Monogram Technologies (NASDAQ:MGRM) announced that management and related parties, including CFO Noel Knape, have completed approximately $1 million in open market purchases of MGRM common stock. CEO Ben Sexson stated this reflects high confidence in their strategy and expectation to create long-term shareholder value. The company outlined upcoming milestones including an FDA meeting by December 2024, seeking regulatory clearance for clinical trials in India with Shalby Hospitals, obtaining FDA clearance for the mBôs™ TKA System, and expanding domestic and international relationships.
Monogram Technologies (NASDAQ:MGRM) reported Q3 2024 financial results, highlighting an upsized and oversubscribed $13 million public offering. The company submitted a 510(k) premarket filing for its mBȏs TKA System and received an Additional Information Request from FDA. Key financials include R&D expenses of $2.2 million, marketing expenses of $1.8 million, and a net loss of $5.0 million. Cash position stood at $16.6 million as of September 30, 2024. The company secured a strategic collaboration with Shalby for multicenter clinical trials in India and was named Orthopedic Joint Replacement Company of the Year 2024.
Monogram Technologies (NASDAQ:MGRM), an AI-driven robotics company focused on orthopedic surgery, has announced its upcoming Third Quarter 2024 earnings conference call scheduled for Tuesday, November 19, 2024, at 4:30 p.m. Eastern Time. CEO Ben Sexson and CFO Noel Knape will host the call to discuss financial results for the quarter ended September 30, 2024, and key milestones. A presentation will accompany the webcast, accessible through the company's investor relations website. The call will be available for replay until February 19, 2025.
Monogram Technologies (NASDAQ:MGRM) has been named Orthopedic Joint Replacement Company of the Year 2024 by Medical Tech Outlook. The award recognizes the company's stellar reputation and trust among customers and industry peers, particularly highlighting their mBôs TKA Precision Robotic Surgical System. The selection process involved an exhaustive evaluation by C-level executives, industry thought leaders, and the editorial board, following numerous nominations from Medical Tech Outlook's subscribers.
FAQ
What is the current stock price of Monogram Orthopaedics (MGRM)?
What is the market cap of Monogram Orthopaedics (MGRM)?
